BMY:NYSE
Bristol-Myers Squibb Co
$67.23
arrow_downward
-0.50%(-0.34) 1D
Aug 27, 1:41:56 PM GMT-4 · USD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMY...
Open
$66.59
High
$67.47
Low
$66.20
Mkt. cap
137.33B
Avg. vol.
11.22M
Volume
1.94M
Dividend
3.75%
Quarterly dividend
$0.63
Ex-dividend date
Jul 2, 2026
P/E ratio
14.81
52-wk high
$68.64
52-wk low
$42.52
EPS
$4.54
Beta
0.22
Shares outstanding
2.04B
No. of employees
32K
Open
$66.59
High
$67.47
Low
$66.20
Mkt. cap
137.33B
Avg. vol.
11.22M
Volume
1.94M
Dividend
3.75%
Quarterly dividend
$0.63
Ex-dividend date
Jul 2, 2026
P/E ratio
14.81
52-wk high
$68.64
52-wk low
$42.52
EPS
$4.54
Beta
0.22
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
TipRanks
·
1 hour ago
Bristol-Myers Squibb Extends Deucravacitinib Program, Signaling Long-Term Autoimmune Ambitions
Zacks
·
3 hours ago
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
Yahoo Finance
·
3 hours ago
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
MarketBeat
·
6 hours ago
Parvin Asset Management LLC Buys Shares of 19,245 Bristol Myers Squibb Company $BMY
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Analyst ratings
Based on 20 analysts giving stock ratings to BMY in the past 3 months
Buy
Buy
9
Hold
10
Sell
1
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for BMY in the last 3 months.
Highest
Current $67.23
$80.00 (+18.99%)
Average
$67.28 (+0.07%)
Lowest
$40.00 (-40.50%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Courtney Breen Bernstein | Hold | Maintained | - | - | 08/20/2026 |
Michael Yee UBS | Buy | Maintained | $80.00 | +19% | 08/20/2026 |
Evan Seigerman BMO Capital | Hold | Maintained | $60.00 | -10.8% | 08/17/2026 |
Louise Chen Scotiabank | Hold | Maintained | $60.00 | -10.8% | 08/14/2026 |
Geoff Meacham Citi | Hold | Maintained | $70.00 | +4.1% | 08/14/2026 |
Matt Phipps William Blair | Hold | Maintained | - | - | 08/14/2026 |
Terence Flynn Morgan Stanley | Sell | Maintained | $40.00 | -40.5% | 08/14/2026 |
Emily Field Barclays | Buy | Reiterated | $75.00 | +11.6% | 08/11/2026 |
Jasper Hellweg Argus Research | Buy | Upgraded | $75.00 | +11.6% | 08/04/2026 |
Chris Schott J.P. Morgan | Buy | Maintained | $73.00 | +8.6% | 08/04/2026 |
Unknown Analyst Berenberg Bank | Hold | Maintained | $65.00 | -3.3% | 08/03/2026 |
Trung Huynh RBC Capital | Hold | Maintained | $64.00 | -4.8% | 08/04/2026 |
Jason Gerberry Bank of America Securities | Buy | Reiterated | $71.00 | +5.6% | 08/03/2026 |
Carter Gould Cantor Fitzgerald | Hold | Maintained | $59.00 | -12.2% | 07/30/2026 |
Srikripa Devarakonda Truist Financial | Buy | Reiterated | $70.00 | +4.1% | 07/31/2026 |
Seamus Fernandez Guggenheim | Buy | Reiterated | $75.00 | +11.6% | 07/31/2026 |
Mohit Bansal Wells Fargo | Hold | Reiterated | $65.00 | -3.3% | 07/31/2026 |
David Amsellem Piper Sandler | Buy | Reiterated | $75.00 | +11.6% | 07/28/2026 |
Asad Haider Goldman Sachs | Hold | Maintained | $61.00 | -9.3% | 07/20/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $73.00 | +8.6% | 06/01/2026 |
Unknown Analyst TD Cowen | Hold | Maintained | $57.00 | -15.2% | 05/18/2026 |
Unknown Analyst Erste Group | Hold | Maintained | - | - | 04/01/2026 |
Rajesh Kumar HSBC | Hold | Maintained | $60.00 | -10.8% | 03/17/2026 |
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.04 / $1.60
+27.74%beat
arrow_upward
Revenue / Est. (USD)
12.97B / 11.74B
+10.53%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 12.22B | 12.50B | 11.49B | 12.97B |
Cost of goods sold | 3.31B | 3.51B | 3.41B | 3.71B |
Cost of revenue | 3.31B | 3.51B | 3.41B | 3.71B |
Research and development expenses | 2.43B | 2.56B | 2.24B | 2.54B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.79B | 2.09B | 1.61B | 1.82B |
Operating expense | 5.05B | 5.47B | 4.28B | 4.80B |
Total operating expenses | 8.36B | 8.98B | 7.69B | 8.51B |
Operating income | 3.86B | 3.52B | 3.80B | 4.46B |
Other non operating income | 529.00M | 544.00M | 125.00M | 106.00M |
EBT including unusual items | 3.11B | 1.47B | 3.24B | 4.09B |
EBT excluding unusual items | 4.07B | 3.86B | 3.65B | 4.35B |
Income tax expense | 919.00M | 384.00M | 561.00M | 770.00M |
Effective tax rate | 29.51% | 26.12% | 17.32% | 18.84% |
Other operating expenses | - | - | - | - |
Net income | 2.20B | 1.09B | 2.68B | 3.32B |
Net profit margin | 18.01% | 8.69% | 23.30% | 25.57% |
Earnings per share | 1.63 | 1.26 | 1.58 | 2.04 |
Interest and investment income | 161.00M | 148.00M | 104.00M | 101.00M |
Interest expense | -482.00M | -432.00M | -406.00M | -403.00M |
Net interest expenses | -321.00M | -284.00M | -302.00M | -302.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.91B | 4.54B | 4.41B | 5.08B |
Gain or loss from assets sale | -9.00M | - | -34.00M | -142.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
AI content may include mistakes. Learn more